nach oben

Erschienen in:

24.01.2020 | Clinical trial

Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen

verfasst von: Cristina Ferraris, Barbara Ballestra, Chiara Listorti, Vera Cappelletti, Carolina Reduzzi, Gianfranco P. Scaperrotta, Iolanda Pulice, Eleonora G. A. Ferrari, Secondo Folli, Luigi Mariani, Gabriele Martelli

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether a red clover preparation plus dietary intervention administered to premenopausal women with breast cancer (BC), improves menopausal symptoms due to anti-oestrogen treatment, and hence promotes compliance with tamoxifen, prevents weight gain and is safe.

Methods

Surgically-treated premenopausal women with oestrogen receptor (ER) positive disease taking tamoxifen were recruited to a prospective double-blind randomized trial (NCT03844685). The red clover group (N = 42) received one oral tablet/day (Promensil^® Forte) containing 80 mg red clover extract for 24 months. The placebo group (N = 39) received one oral tablet/day without active ingredient. All women were encouraged to follow a Mediterranean-type diet and keep active. Outcomes were Menopausal Rating Score (MRS), body mass index (BMI), waist and hip girth, insulin resistance, and levels of cholesterol, triglycerides, and sex hormones. As safety indicators, endometrial thickness, breast density, and effects of patient serum on ER-positive BC cell lines were investigated.

Results

MRS reduced significantly (p < 0.0001) with no between-group difference (p = 0.69). The red clover group had significantly greater reductions in BMI and waist circumference (p < 0.0001 both cases). HDL cholesterol increased significantly in both groups (p = 0.01). Hormone levels and insulin resistance changed little. Endometrial thickness remained constant (p = 0.93). Breast density decreased significantly in both groups (p < 0.0001). Proliferation and oestrogen-regulated gene expression didn’t differ in cell lines treated with serum from each group.

Conclusions

This is the first trial to assess red clover in BC patients on tamoxifen. The preparation proved safe clinically and in vitro, and was associated with reduced BMI and waist circumference, but the diet-lifestyle intervention probably improved the menopausal symptoms.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRef

Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484. https://doi.org/10.1056/NEJM198902233200802 CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl 365(9472):1687–1717. https://doi.org/10.1016/S0140-6736(05)66544-0 CrossRef

Paranjpe R, John G, Trivedi M, Abughosh S (2019) Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat 174:297–305. https://doi.org/10.1007/s10549-018-05073-z CrossRefPubMed

Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128. https://doi.org/10.1200/JCO.2009.25.9655 CrossRefPubMedPubMedCentral

Wassermann J, Rosenberg SM (2017) Treatment decisions and adherence to adjuvant endocrine therapy in breast cancer. Curr Breast Cancer Rep 9:100–110. https://doi.org/10.1007/s12609-017-0248-5 CrossRef

Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdz173 CrossRefPubMed

Condorelli R, Vaz-Luis I (2018) Managing side effects in adjuvant endocrine therapy for breast cancer. Expert Rev Anticancer Ther 18(11):1101–1112. https://doi.org/10.1080/14737140.2018.1520096 CrossRefPubMed

Fritz H, Seely D, Flower G et al (2013) Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS ONE 8(11):e81968. https://doi.org/10.1371/journal.pone.0081968 CrossRefPubMedPubMedCentral

10.

Hüser S, Guth S, Joost HG et al (2018) Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation. Arch Toxicol 92(9):2703–2748. https://doi.org/10.1007/s00204-018-2279-8 CrossRefPubMedPubMedCentral

11.

Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (2005) Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26(3):465–478CrossRef

12.

Schmidt M, Arjomand-Wölkart K, Birkhäuser MH et al (2016) Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. Gynecol Endocrinol 32(6):427–430. https://doi.org/10.3109/09513590.2016.1152240 CrossRefPubMed

13.

Myers SP, Vigar V (2017) Effects of a standardised extract of Trifolium pratense (Promensil) at a dosage of 80 mg in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine 24:141–147. https://doi.org/10.1016/j.phymed.2016.12.003 CrossRefPubMed

14.

Powles TJ, Howell A, Evans DG et al (2008) Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 14(1):6–12. https://doi.org/10.1258/mi.2007.007033 CrossRefPubMed

15.

Mueller M, Jungbauer A (2008) Red clover extract: a putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome. Menopause 15(6):1120–1131. https://doi.org/10.1097/gme.0b013e31817062ce CrossRefPubMed

16.

Jungbauer A, Medjakovic S (2014) Phytoestrogens and the metabolic syndrome. J Steroid Biochem Mol Biol 139:277–289. https://doi.org/10.1016/j.jsbmb.2012.12.009 CrossRefPubMed

17.

Masala G, Bendinelli B, Assedi M et al (2017) Up to one-third of breast cancer cases in post-menopausal Mediterranean women might be avoided by modifying lifestyle habits: the EPIC Italy study. Breast Cancer Res Treat 161(2):311–320. https://doi.org/10.1007/s10549-016-4047-x CrossRefPubMed

18.

Vergnaud AC, Romaguera D, Peeters PH et al (2013) Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: results from the European Prospective Investigation into Nutrition and Cancer cohort study1,4. Am J Clin Nutr 97(5):1107–1120. https://doi.org/10.3945/ajcn.112.049569 CrossRefPubMed

19.

Chen Y, Wen YY, Li ZR, Luo DL, Zhang XH (2016) The molecular mechanisms between metabolic syndrome and breast cancer. Biochem Biophys Res Commun 471(4):391–395. https://doi.org/10.1016/j.bbrc.2016.02.034 CrossRefPubMed

20.

Nichols HB, Trentham-Dietz A, Egan KM et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer and cardiovascular disease mortality. Cancer Epidemiol Biomark Prev 18(5):1403–1409. https://doi.org/10.1158/1055-9965.EPI-08-1094 CrossRef

21.

Biganzoli E, Desmedt C, Fornili M et al (2017) Recurrence dynamics of breast cancer according to baseline body mass index. Eur J Cancer 87:10–20. https://doi.org/10.1016/j.ejca.2017.10.007 CrossRefPubMed

22.

Shike M, Doane AS, Russo L et al (2014) The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju189 CrossRefPubMedPubMedCentral

23.

Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474–2477. https://doi.org/10.1093/carcin/bgg198 CrossRefPubMed

24.

Raju KS, Taneja I, Valicherla GR et al (2015) No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats. Sci Rep 5:16126. https://doi.org/10.1038/srep16126 CrossRefPubMedPubMedCentral

25.

Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT (2004) The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2:45. https://doi.org/10.1186/1477-7525-2-45 CrossRefPubMedPubMedCentral

26.

Yumuk V, Tsigos C, Fried M et al (2015) European guidelines for obesity management in adults. Obes Facts 8(6):402–424. https://doi.org/10.1159/000442721 CrossRefPubMedPubMedCentral

27.

Posadzki P, Watson LK, Ernst E (2013) Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med 13(1):7–12. https://doi.org/10.7861/clinmedicine.13-1-7 CrossRef

28.

Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144(10):4562–4574. https://doi.org/10.1210/en.2003-0567 CrossRefPubMed

29.

Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Can Res 64(4):1522–1533. https://doi.org/10.1158/0008-5472 CrossRef

30.

Nomura SJO, Hwang YT, Gomez SL et al (2018) Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors. Breast Cancer Res Treat 168(2):467–479. https://doi.org/10.1007/s10549-017-4578-9 CrossRefPubMed

31.

Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J (2013) Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001395.pub4 CrossRefPubMedPubMedCentral

32.

Agresti R, Meneghini E, Baili P et al (2016) Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat 157(1):179–189. https://doi.org/10.1007/s10549-016-3802-3 CrossRefPubMed

33.

Sebastiani F, Cortesi L, Sant M et al (2016) Increased incidence of breast cancer in postmenopausal women with high body mass index at the Modena Screening Program. J Breast Cancer 19(3):283–291. https://doi.org/10.4048/jbc.2016.19.3.283 CrossRefPubMedPubMedCentral

34.

Chedraui P, San Miguel G, Hidalgo L, Morocho N, Ross S (2008) Effect of Trifolium pratense-derived isoflavones on the lipid profile of postmenopausal women with increased body mass index. Gynecol Endocrinol 24(11):620–624. https://doi.org/10.1080/09513590802288283 CrossRefPubMed

35.

Terzic MM, Dotlic J, Maricic S, Mihailovic T, Tosic-Race B (2009) Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women. J Obstet Gynaecol Res 35(6):1091–1095. https://doi.org/10.1111/j.1447-0756.2009.001059.x CrossRefPubMed

36.

Sundaresan A, Radhiga T, Deivasigamani B (2018) Biological activity of biochanin A: a review. Asian J Pharm Pharmacol 4(1):1–5CrossRef

37.

Agnoli C, Berrino F, Abagnato CA et al (2010) Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr Metab Cardiovasc Dis 20(1):41–48. https://doi.org/10.1016/j.numecd.2009.02.006 CrossRefPubMed

38.

Sieri S, Krogh V, Bolelli G et al (2009) Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomark Prev 18(1):169–176. https://doi.org/10.1158/1055-9965 CrossRef

39.

Byrne C, Ursin G, Martin CF et al (2017) Mammographic density change with estrogen and progestin therapy and breast cancer risk. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx001 CrossRefPubMedPubMedCentral

40.

Atkinson C, Warren RM, Sala E et al (2004) Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast Cancer Res 6(3):R170–R179. https://doi.org/10.1186/bcr773 CrossRefPubMedPubMedCentral

41.

Imhof M, Gocan A, Reithmayr F et al (2006) Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 55(1):76–81. https://doi.org/10.1016/j.maturitas.2006.01.006 CrossRefPubMed

42.

Hu R, Hilakivi-Clarke L, Clarke R (2015) Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol Lett 9(4):1495–1501. https://doi.org/10.3892/ol.2015.2962 CrossRefPubMedPubMedCentral

43.

Khazaei M, Pazhouhi M (2019) Antiproliferative effect of trifolium pratens L. extract in human breast cancer cells. Nutr Cancer 71(1):128–140. https://doi.org/10.1080/01635581.2018.1521443 CrossRefPubMed

44.

Ong SKL, Shanmugam MK, Fan L et al (2019) Focus on formononetin: anticancer potential and molecular targets. Cancers 11(5):611. https://doi.org/10.3390/cancers11050611 CrossRefPubMedCentral

Titel: Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen
verfasst von: Cristina Ferraris
Barbara Ballestra
Chiara Listorti
Vera Cappelletti
Carolina Reduzzi
Gianfranco P. Scaperrotta
Iolanda Pulice
Eleonora G. A. Ferrari
Secondo Folli
Luigi Mariani
Gabriele Martelli
Publikationsdatum: 24.01.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05534-4

Springer Medizin

Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen